問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Colorectal Surgery

Division of Hematology & Oncology

Division of General Internal Medicine

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Taichung Veterans General Hospital (在職)

Division of General Surgery

Division of General Internal Medicine

Division of Nephrology

Division of Hematology & Oncology

更新時間：2023-09-19

李冠德Lee, Kuan-Der
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

Recruiting Trial

39Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李冠德

List

78Cases

2018-09-01 - 2020-02-29

Phase I

A Phase I, open-label study to evaluate safety and tolerability of PB101 in combination with standard treatment, EGFR-TKI (Gefitinib or Erlotinib), in EGFR-mutated advanced non-small cell lung cancer.

  • Condition/Disease

    EGFR-mutated advanced non-small cell lung cancer

  • Test Drug

    PB101

Participate Sites
2Sites

Recruiting2Sites

2013-08-22 - 2015-06-30

Phase III

A randomized, double-blind, double-dummy, parallel group, international multicenter study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer.

  • Condition/Disease

    nausea and vomiting

  • Test Drug

    netupitant-palonosetron Fixed Dose Combination (FDC)

Participate Sites
7Sites

Terminated7Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2007-03-31 - 2009-09-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2004-09-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-06-01 - 2012-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-03-01 - 2023-03-01

Phase III

Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma

  • Condition/Disease

    Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma

  • Test Drug

    Lenalidomide (CC-5013)

Participate Sites
6Sites

Terminated5Sites

2016-06-01 - 2019-05-31

Phase I

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors

  • Condition/Disease

    Advanced Tumors

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Terminated6Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

侯明模
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2012-12-03 - 2018-09-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2007-03-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB